- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- Teva receives FDA approval for generic Lovaza
FORT WASHINGTON, Pa. McNeil Consumer Healthcare on Friday voluntarily recalled all lots that have not yet expired of certain over-the-counter children’s and infants’ liquid products in consultation with the Food and Drug Administration.
McNeil Consumer initiated the recall because some of these products may not meet required quality standards, though no adverse medical events have been reported, the company stated. “However, as a precautionary measure, parents and caregivers should not administer these products to their children.”
Some of the products included in the recall may contain a higher concentration of active ingredient than is specified; others may contain inactive ingredients that may not meet internal testing requirements; and others may contain tiny particles.
“While the potential for serious medical events is remote, the company advises consumers who have purchased these recalled products to discontinue use,” McNeil stated.
The company is conducting a comprehensive quality assessment across its manufacturing operations and has identified corrective actions that will be implemented before new manufacturing is initiated at the plant where the recalled products were made.
For a full list of products recalled, visit http://www.mcneilproductrecall.com/page.jhtml?id=/include/new_recall.inc